Open Access. Powered by Scholars. Published by Universities.®
- Discipline
Articles 1 - 4 of 4
Full-Text Articles in Medicine and Health Sciences
Autophagy Modulation As A Treatment Of Amyloid Diseases, Zoe Mputhia, Eugene Hone, Timir Tripathi, Tim Sargeant, Ralph Martins, Prashant Bharadwaj
Autophagy Modulation As A Treatment Of Amyloid Diseases, Zoe Mputhia, Eugene Hone, Timir Tripathi, Tim Sargeant, Ralph Martins, Prashant Bharadwaj
Research outputs 2014 to 2021
Amyloids are fibrous proteins aggregated into toxic forms that are implicated in several chronic disorders. More than 30 diseases show deposition of fibrous amyloid proteins associated with cell loss and degeneration in the affected tissues. Evidence demonstrates that amyloid diseases result from protein aggregation or impaired amyloid clearance, but the connection between amyloid accumulation and tissue degeneration is not clear. Common examples of amyloid diseases are Alzheimer's disease (AD), Parkinson's disease (PD) and tauopathies, which are the most common forms of neurodegenerative diseases, as well as polyglutamine disorders and certain peripheral metabolic diseases. In these diseases, increased accumulation of toxic …
Validation Of A Priori Candidate Alzheimer’S Disease Snps With Brain Amyloid-Beta Deposition, Michael Vacher, Tenielle Porter, Victor L. Villemagne, Lidija Milicic, Madeline Peretti, Christopher C. Fowler, Ralph Martins, Stephanie Rainey-Smith, David Ames, Colin L. Masters, Christopher C. Rowe, James D. Doecke, Simon M. Laws
Validation Of A Priori Candidate Alzheimer’S Disease Snps With Brain Amyloid-Beta Deposition, Michael Vacher, Tenielle Porter, Victor L. Villemagne, Lidija Milicic, Madeline Peretti, Christopher C. Fowler, Ralph Martins, Stephanie Rainey-Smith, David Ames, Colin L. Masters, Christopher C. Rowe, James D. Doecke, Simon M. Laws
Research outputs 2014 to 2021
The accumulation of brain amyloid β (Aβ) is one of the main pathological hallmarks of Alzheimer’s disease (AD). However, the role of brain amyloid deposition in the development of AD and the genetic variants associated with this process remain unclear. In this study, we sought to identify associations between Aβ deposition and an a priori evidence based set of 1610 genetic markers, genotyped from 505 unrelated individuals (258 Aβ+ and 247 Aβ−) enrolled in the Australian Imaging, Biomarker & Lifestyle (AIBL) study. We found statistically significant associations for 6 markers located within intronic regions of 6 genes, including AC103796.1-BDNF, PPP3R1, …
Rates Of Age- And Amyloid Β-Associated Cortical Atrophy In Older Adults With Superior Memory Performance, Christa Dang, Nawaf Yassi, Karra D. Harrington, Ying Xia, Yen Ying Lim, David Ames, Simon M. Laws, Martha Hickey, Stephanie Rainey-Smith, Hamid R. Sohrabi, James D. Doecke, Jurgen Fripp, Olivier Salvado, Peter J. Snyder, Michael Weinborn, Victor L. Villemagne, Christopher C. Rowe, Colin L. Masters, Paul Maruff
Rates Of Age- And Amyloid Β-Associated Cortical Atrophy In Older Adults With Superior Memory Performance, Christa Dang, Nawaf Yassi, Karra D. Harrington, Ying Xia, Yen Ying Lim, David Ames, Simon M. Laws, Martha Hickey, Stephanie Rainey-Smith, Hamid R. Sohrabi, James D. Doecke, Jurgen Fripp, Olivier Salvado, Peter J. Snyder, Michael Weinborn, Victor L. Villemagne, Christopher C. Rowe, Colin L. Masters, Paul Maruff
Research outputs 2014 to 2021
Introduction: Superior cognitive performance in older adults may reflect underlying resistance to age-associated neurodegeneration. While elevated amyloid b (Ab) deposition (Ab1) has been associated with increased cortical atrophy, it remains unknown whether “SuperAgers” may be protected from Ab-associated neurodegeneration. Methods: Neuropsychologically defined SuperAgers (n 5 172) and cognitively normal for age (n 5 172) older adults from the Australian Imaging, Biomarkers and Lifestyle study were case matched. Rates of cortical atrophy over 8 years were examined by SuperAger classification and Ab status. Results: Of the case-matched SuperAgers and cognitively normal for age older adults, 40.7% and 40.1%, respectively, were Ab1. …
Application Of The Nia-Aa Research Framework: Towards A Biological Definition Of Alzheimer’S Disease Using Cerebrospinal Fluid Biomarkers In The Aibl Study, S. C. Burnham, P. M. Coloma, Q.-X. Li, S. Collins, G. Savage, S. Laws, J. Doecke, P. Maruff, R. N. Martins, D. Ames, C. C. Rowe, C. L. Masters, V. L. Villemagne
Application Of The Nia-Aa Research Framework: Towards A Biological Definition Of Alzheimer’S Disease Using Cerebrospinal Fluid Biomarkers In The Aibl Study, S. C. Burnham, P. M. Coloma, Q.-X. Li, S. Collins, G. Savage, S. Laws, J. Doecke, P. Maruff, R. N. Martins, D. Ames, C. C. Rowe, C. L. Masters, V. L. Villemagne
Research outputs 2014 to 2021
BACKGROUND: The National Institute on Aging and Alzheimer’s Association (NIA-AA) have proposed a new Research Framework: Towards a biological definition of Alzheimer’s disease, which uses a three-biomarker construct: Aß-amyloid, tau and neurodegeneration AT(N), to generate a biomarker based definition of Alzheimer’s disease. OBJECTIVES: To stratify AIBL participants using the new NIA-AA Research Framework using cerebrospinal fluid (CSF) biomarkers. To evaluate the clinical and cognitive profiles of the different groups resultant from the AT(N) stratification. To compare the findings to those that result from stratification using two-biomarker construct criteria (AT and/or A(N)). DESIGN: Individuals were classified as being positive or negative …